Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting

被引：0
作者：
Ahmet Emre Eskazan
机构：
[1] Istanbul University,Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine
来源：
European Journal of Clinical Pharmacology | 2016年 / 72卷
关键词：
Imatinib; Tacrolimus; Chronic Myeloid Leukemia; Calcineurin Inhibitor; Lymphoid Leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1537 / 1538
页数：1
相关论文
共 45 条
  • [41] Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study
    Tanguy-Schmidt, Aline
    Rousselot, Philippe
    Chalandon, Yves
    Cayuela, Jean-Michel
    Hayette, Sandrine
    Vekemans, Marie-Christiane
    Escoffre, Martine
    Huguet, Francoise
    Rea, Delphine
    Delannoy, Andre
    Cahn, Jean-Yves
    Vernant, Jean-Paul
    Ifrah, Norbert
    Dombret, Herve
    Thomas, Xavier
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (01) : 150 - 155
  • [42] Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
    Ashaye, Ajibade
    Shi, Ling
    Aldoss, Ibrahim
    Montesinos, Pau
    Vachhani, Pankit
    Rocha, Vanderson
    Papayannidis, Cristina
    Leonard, Jessica T.
    Baer, Maria R.
    Ribera, Jose-Maria
    McCloskey, James
    Wang, Jianxiang
    Rane, Deepali
    Guo, Shien
    [J]. CANCER MEDICINE, 2025, 14 (07):
  • [43] Characteristics of Patients With Development of Large Granular Lymphocyte Expansion Among Dasatinib-Treated Patients With Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
    Ito, Yoshikiyo
    Miyamoto, Toshihiro
    Kamimura, Tomohiko
    Aoki, Kenichi
    Henzan, Hideho
    Aoki, Takatoshi
    Shiratsuchi, Motoaki
    Kato, Koji
    Nagafuji, Koji
    Ogawa, Ryosuke
    Eto, Tetsuya
    Iwasaki, Hiromi
    Akashi, Koichi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (03) : e47 - e54
  • [44] Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
    Li, Nanxin
    Yang, Xi
    Fan, Liangyi
    Totev, Todor
    Guerin, Annie
    Chen, Lei
    Bhattacharyya, Subrata
    Joseph, George
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 328 - 336
  • [45] A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)
    B. Wassmann
    N. Gökbuget
    U. J. Scheuring
    A. Binckebanck
    R. Reutzel
    H. Gschaidmeier
    D. Hoelzer
    O. G. Ottmann
    GMALL Study Group
    [J]. Annals of Hematology, 2003, 82 : 716 - 720
12345